enGene Therapeutics Inc. (ENGN) research
enGene Therapeutics Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $1.94
- As of
enGene Therapeutics Inc. (ENGN): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-08.
As of . Source: SEC EDGAR filings for ENGN. Method and limitations.
Share the ENGN intelligence card
See the full ENGN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ENGN on one page. Preview it with sample data, then open it live with a free account.
Preview the ENGN dossierActive signals for ENGN
- mediumEARNINGS_MISS
Q3-2026: Missed consensus by 7.2%, EPS $-0.47 vs $-0.4386 estimate
- highCONSENSUS_BUY
7 tracked funds increased ENGN this 2026Q2, institutional consensus
- highCONSENSUS_BUY
5 tracked funds increased ENGN this 2026Q2, institutional consensus
- mediumNEW_POSITION
Point72 Asset Management, L.P. new position in ENGN
- mediumNEW_POSITION
MILLENNIUM MANAGEMENT LLC new position in ENGN
FREE, NO ACCOUNT
Every signal on ENGN, as it fires
You are seeing 5 of 17 signals recorded on ENGN since 2026-05-29.
The five above landed across 3 days. The other 12 were recorded on 4 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ENGN (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 29286X101 · 2026Q2 | $1.7M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 29286X101 · 2026Q2 | $1.4M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 29286X101 · 2026Q2 | $1.2M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 29286X101 · 2026Q2 | $285K | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 29286X101 · 2026Q2 | $24K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ENGN
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ENGN against its peers
ENGN's return on equity of -69.9% ranks in the 74th percentile of 16 Biotechnology sub-industry peers, fiscal periods ending between 2025-10-31 and 2025-12-31.
| Metric | ENGN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 2.0M | n/a | 13 |
| Operating margin | n/a | -1326.9% | n/a | 10 |
| Net margin | n/a | -1580.9% | n/a | 10 |
| Return on equity | -69.9% | -90.4% | 74 | 16 |
Peers (21): SPRB, CRBU, ARMP, SMNR, TNYA, NRXP, CLLS, KRRO, HURA, INO, VTVT, HUMA, FHTX, CRBP, ABOS, UNCY, COYA, MOLN, MENS, GNLX, VYGR. Left out: BETRF (period gap), TLSA (period gap), RNA (no annual filing), OTLK (no annual filing). Fiscal periods ending between 2025-10-31 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (ENGN: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ENGN signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ENGNand get the insider, 13F, options, and confluence read in one view.